Patrizia Mancuso Selected Research

Bevacizumab (Avastin)

1/2013	Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan.
6/2012	Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab.
2/2011	Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.
12/2009	Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab.
3/2009	Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
10/2008	Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.
9/2003	Strategies to investigate circulating endothelial cells in cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Patrizia Mancuso Research Topics

Disease

26	Neoplasms (Cancer) 03/2023 - 01/2003
15	Breast Neoplasms (Breast Cancer) 01/2021 - 01/2003
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 03/2023 - 06/2002
3	Triple Negative Breast Neoplasms 03/2023 - 01/2021
3	Lymphoma (Lymphomas) 01/2018 - 01/2003
2	B-Cell Lymphoma (Lymphoma, B Cell) 03/2023 - 10/2003
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020 - 11/2008
2	Glioblastoma (Glioblastoma Multiforme) 01/2014 - 01/2013
2	Vascular Remodeling 10/2010 - 01/2008
2	Colorectal Neoplasms (Colorectal Cancer) 10/2010 - 09/2003
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 09/2022
1	COVID-19 10/2020
1	Residual Neoplasm 01/2020
1	Type 2 Diabetes Mellitus (MODY) 03/2015
1	Disease Progression 06/2012
1	Pathologic Neovascularization 02/2011
1	Melanoma (Melanoma, Malignant) 02/2011
1	Carcinogenesis 02/2011
1	Polycythemia (Erythrocytosis) 08/2010
1	Waldenstrom Macroglobulinemia (Macroglobulinemia) 05/2010
1	Cardiotoxicity 05/2010
1	Headache (Headaches) 03/2009
1	Hypertension (High Blood Pressure) 03/2009
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/2008
1	Leukemia 11/2008
1	Hypoxia (Hypoxemia) 01/2008
1	Vascular System Injuries 02/2005
1	Cardiovascular Diseases (Cardiovascular Disease) 02/2005
1	Vascular Diseases (Vascular Disease) 02/2005
1	Hematologic Neoplasms (Hematological Malignancy) 06/2004
1	Abscess 10/2003
1	Infections 10/2003

Drug/Important Bio-Agent (IBA)

7	Cyclophosphamide (Cytoxan)FDA LinkGeneric 03/2023 - 08/2003
7	Bevacizumab (Avastin)FDA Link 01/2013 - 09/2003
6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2013 - 01/2003
5	Biomarkers (Surrogate Marker)IBA 09/2022 - 02/2005
3	Vinorelbine (Navelbine)FDA LinkGeneric 03/2023 - 01/2018
3	RNA (Ribonucleic Acid)IBA 10/2020 - 06/2004
3	Capecitabine (Xeloda)FDA Link 06/2012 - 10/2008
2	Fluorouracil (Carac)FDA LinkGeneric 01/2018 - 03/2009
2	Metformin (Glucophage)FDA LinkGeneric 01/2016 - 03/2015
2	Cell-Free Nucleic AcidsIBA 10/2010 - 06/2004
2	Rituximab (Mabthera)FDA Link 05/2010 - 10/2003
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2009 - 05/2003
2	Paclitaxel (Taxol)FDA LinkGeneric 03/2009 - 09/2008
2	Monoclonal AntibodiesIBA 05/2003 - 06/2002
1	Doxorubicin (Adriamycin)FDA LinkGeneric 03/2023
1	Cytarabine (Cytosar-U)FDA LinkGeneric 03/2023
1	PlatinumIBA 03/2023
1	Everolimus FDA Link 09/2022
1	venetoclaxIBA 01/2020
1	Proteins (Proteins, Gene)FDA Link 01/2017
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2017
1	Metalloproteases (Metalloproteinases)IBA 01/2017
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2016
1	Atenolol (Tenormin)FDA LinkGeneric 01/2016
1	Phenformin (Fenformin)IBA 03/2015
1	BiguanidesIBA 03/2015
1	pimonidazoleIBA 03/2015
1	Phenobarbital (Luminal)FDA Link 10/2013
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2013
1	Hemoglobins (Hemoglobin)IBA 06/2012
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 06/2012
1	erucylphosphocholineIBA 01/2012
1	Glucose (Dextrose)FDA LinkGeneric 01/2012
1	Sunitinib (Sutent)FDA Link 09/2011
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 02/2011
1	Activin Receptors (Activin Receptor)IBA 02/2011
1	Phosphotransferases (Kinase)IBA 02/2011
1	matrigelIBA 02/2011
1	Glutamic Acid (Glutamate)FDA Link 08/2010
1	Codon (Codons)IBA 08/2010
1	Amino Acids FDA Link 08/2010
1	NucleotidesIBA 08/2010
1	Erythropoietin Receptors (Erythropoietin Receptor)IBA 08/2010
1	Cladribine FDA LinkGeneric 05/2010
1	AnthracyclinesIBA 03/2009
1	Epirubicin (Ellence)FDA LinkGeneric 03/2009
1	taxaneIBA 03/2009
1	Cisplatin (Platino)FDA LinkGeneric 03/2009
1	Gemcitabine FDA Link 09/2008
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 02/2005
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 06/2004
1	cadherin 5IBA 06/2004
1	Chlorambucil (Leukeran)FDA Link 10/2003
1	Angiogenesis InhibitorsIBA 09/2003
1	Trastuzumab (Herceptin)FDA Link 05/2003
1	EndostatinsIBA 01/2003
1	N 30IBA 01/2003

Therapy/Procedure

15	Therapeutics 03/2023 - 01/2003
11	Drug Therapy (Chemotherapy) 03/2022 - 01/2003
1	Immunotherapy 03/2022
1	Aftercare (After-Treatment) 01/2014
1	Mammaplasty (Breast Reconstruction) 01/2012
1	Colectomy 10/2010
1	Transplantation 11/2008